MIRA MIRA Pharmaceuticals Inc

0.30 (6.9%)
After Hours
Last Updated: 16:00:03
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 90,414
Bid Price 4.54
Ask Price 5.15
News -
Day High 4.94


52 Week Range


Day Low 4.35
Company Name Stock Ticker Symbol Market Type
MIRA Pharmaceuticals Inc MIRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.30 6.9% 4.65 16:00:03
Open Price Low Price High Price Close Price Prev Close
4.35 4.35 4.94 4.65 4.35
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
951 90,414 $ 4.72 $ 426,933 - 3.00 - 7.9799
Last Trade Time Type Quantity Stock Price Currency
16:00:00 20 $ 4.65 USD

MIRA Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 68.73M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

MIRA Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MIRA Message Board. Create One! See More Posts on MIRA Message Board See More Message Board Posts

Historical MIRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.185.303.924.3767,7830.4711.24%
1 Month6.426.773.004.47199,495-1.77-27.57%
3 Months7.007.97993.005.22147,246-2.35-33.57%
6 Months7.007.97993.005.22147,246-2.35-33.57%
1 Year7.007.97993.005.22147,246-2.35-33.57%
3 Years7.007.97993.005.22147,246-2.35-33.57%
5 Years7.007.97993.005.22147,246-2.35-33.57%

MIRA Pharmaceuticals Description

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.